|Articles|December 1, 2012
Optimizing Investigator Fees
Author(s)Industry Standard Research
Industry Standard Research
Advertisement
Awell documented 2008 study titled "Sensible Approaches for Reducing Clinical Trial Costs," http://ctj.sagepub.com/content/5/1/75.abstract found that investigator payments account for a staggering 48% of total trial costs. So it goes without saying that sponsors and CROs can't afford to get the investigator payment level wrong. For sponsors and CROs, not paying market-rate investigator fees impacts both the financial health of the organization and the ability to recruit high-performing and experienced sites. Pay too much and your R&D budget evaporates. Pay too little and it will be difficult to recruit experienced sites.
But planners need to know when to offer more and when to offer less. Industry Standard Research has recently published a study that identifies the factors that drive investigator fees higher and lower and benchmarked these fees across 11 therapy areas.
Intuitively it makes sense that study length and complexity would both influence investigator fees. ISR's study quantified just how much. Investigators indicated that both study length and complexity have a dramatic impact on the amount of the investigator fees. For long and/or complex studies, investigator fees can run 50% to 60% higher than for more standard studies.
Knowing what levers push and pull investigator fees—and by how much—will help optimize the use of budgets industry wide and maybe even improve recruitment rates along the way.
—Industry Standard Research, www.ISRreports.com .
Articles in this issue
almost 13 years ago
Article
The GXP Training Guidelines: Raising Standards Through Competence-Based TrainingNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
- How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
September 11th 2025
- How Recent Policy Changes Could Impact Clinical Research
September 10th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
3
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
4
How Recent Policy Changes Could Impact Clinical Research
5